June 2024 in “Journal of Clinical Oncology” In this retrospective study, combining TACE with Donafenib showed promising results as a first-line treatment for Chinese patients with unresectable hepatocellular carcinoma, yielding a median progression-free survival of 12.8 months and a one-year overall survival rate of 87.5%, along with a favorable safety profile.
1 citations
,
December 2004 in “Hepatology” This study found that in lamivudine-resistant hepatitis B patients, tenofovir significantly reduced HBV DNA levels faster and more consistently than adefovir, reaching undetectable levels in all treated patients by 44 weeks.
4 citations
,
May 2023 in “Cells” In this study, baricitinib treatment improved the differentiation of skin-derived precursors into adipocytes for diseases like Hutchinson-Gilford progeria syndrome, suggesting potential benefits when combined with lonafarnib.
10 citations
,
October 2010 in “Hepatology” This case study suggests that treatment with Pil-Food, intended for hair loss prevention, may have triggered postinfantile giant cell hepatitis with autoimmune characteristics, which showed a rapid and effective response to corticosteroid therapy.
8 citations
,
October 2023 in “Folia Histochemica et Cytobiologica” This study observed that exosomes from adipose mesenchymal stem cells overexpressing hepatocyte growth factor significantly improved liver function and reduced fibrosis in mice with experimentally induced liver injury.